While there are shared principles across development programs, Barr noted that the nuances within immunology, ophthalmology, or chronic care studies can determine whether a trial succeeds or fails.
LOS GATOS, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (ARDS) today announced positive feedback from the European Medicines Agency (EMA) on the Company’s proposed single ...
"We are excited to see Pfizer advancing MesoC2 into clinical development rapidly, highlighting the potential of Nona's Harbour Mice® and integrated ADC platforms to deliver innovative cancer therapies ...
Izotropic announced today it has completed a comprehensive review of its R&D strategy to yield a differentiated offering for the Company's priority markets, while positioning the business for ...
-Remain On Track to Initiate CYC-126's Phase 2 Proof-of-Concept ("POC”) Study in Treatment Resistant Depression ("TRD”) in ...
In understanding what makes the patient voice so essential to successful drug development, let’s take a critical eye to what ...
Sign up for CNN’s Wonder Theory science newsletter. Explore the universe with news on fascinating discoveries, scientific advancements and more. The first ...
“We are particularly gratified to reach concurrence with the FDA on the overall study design, endpoints, and patient populations,” said Aridis CEO Vu Truong. “This provides a clear clinical and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results